Research LetterPatients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis
Section snippets
Acknowledgments
The statements, findings, conclusions, and opinions contained and expressed in this manuscript are based in part on data obtained under license from the IQVIA Legacy PharMetrics Adjudicated Claims Data, All Rights Reserved. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Data were obtained under licensing from IQVIA, and thus requests for data sharing must comply with
References (6)
Aliment Pharmacol Ther
(2015)Clin Gastroenterol Hepatol
(2021)Inflamm Bowel Dis
(2014)
Cited by (3)
Shedding New Light on High-Risk Phenotypes for Pouchitis
2023, Inflammatory Bowel DiseasesVery Early Pouchitis Is Associated with an Increased Likelihood of Chronic Inflammatory Conditions of the Pouch
2023, Digestive Diseases and Sciences
Conflicts of interest These authors disclose the following: Edward L. Barnes has served as a consultant for AbbVie, Gilead, Pfizer, Takeda, and Target RWE. Michael D. Kappelman has served as a consultant for AbbVie, Takeda, Janssen, and Eli Lilly; and has received research support from AbbVie and Janssen. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, and Target Pharmasolutions; and has received research support from Pfizer and Takeda. Hans H. Herfarth has served as a consultant for Alivio, AMAG, Finch, Gilead, Lycera, Merck, Otsuka, Pfizer, PureTech, and Seres; and has received research support from Pfizer and Artizan Biosciences. The remaining authors disclose no conflicts.
Funding This research was supported by grants from the Crohn’s & Colitis Foundation (567497 [ELB]) and the National Institutes of Health (K23DK127157-01 [ELB] and P30DK034987 [RSS]).